Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31529987 | 0.88 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL29424715 | 0.82 | MEN1 (0.38) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL114650 | 0.76 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL9147640 | 0.75 | LMNA (0.44) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL9343755 | 0.74 | LMNA (0.44) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| Phosphoric Acid SCHEMBL6465085 | 0.73 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| Phosphoric Acid SCHEMBL20305093 | 0.73 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL31685308 | 0.67 | LMNA (0.36) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL30612476 | 0.67 | EGFR (0.39) | LMNASMN1; SMN2ALDH1A1MTORTP53 | |
| SCHEMBL31685392 | 0.64 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MTORTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4008334-B1 | MANNOSE-BASED MRNA TARGETED DELIVERY SYSTEM AND USE THEREOF | SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD (CN) | 2024-12-04 | — | — | EP | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | claimed |
| WO-2023178182-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | 10X GENOMICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-4747380-A1 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | CRISPR Therapeutics AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743437-A1 | DIESTER LIPIDS, LIPID NANOPARTICLE CONTAINING DIESTER LIPIDS, AND FORMULATIONS THEREOF | Providence Therapeutics Holdings Inc. (CA) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | RNAV8 BIO INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4728063-A1 | METHODS OF SIMULTANEOUSLY IDENTIFYING OR QUANTIFYING CAPPING AND TAILING MODIFICATIONS OF MESSENGER RNA | Sanofi Pasteur Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4709417-A2 | POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3983545-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3976057-A1 | EXPANDED T CELL ASSAY | ModernaTX, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022066757-A1 | IMPROVED METHODS AND COMPOSITIONS FOR EXPRESSION OF NUCLEIC ACIDS IN CELLS | MYELOID THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3966327-A1 | CRISPR/CAS ALL-IN-TWO VECTOR SYSTEMS FOR TREATMENT OF DMD | Vertex Pharmaceuticals Incorporated (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3958893-A1 | MRNA FORMULATION | eTheRNA Immunotherapies NV (BE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022032154-A2 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109976-A1 | SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS | UPF1, RNGTT, NSUN3 | LMNA 1947/4885SMN1; SMN2 1804/4885ALDH1A1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.